TABLE 5.

Examples of nanoparticle-based gene therapy approaches for ovarian cancer

Gene target Tumor suppressors		NP composition	Target	Refs
Human adenovirus type 5 early region 1A (E1A) Trial drug: “tgDCC-E1”	Plasmid vector	liposome	—	Phase I and II: NCT00102622, 148, 208
	Plasmid vector	PEG-PEI-cholesterol Lipopolymer	—	Phase I: NCT01489371 Phase I: NCT00473954 Phase II: NCT01118052, 149
HSulf-1	Plasmid vector	Heparin-polyethyleneimine nanogels	—	Xenograft, 150
FILIP1L	Plasmid vector	Heparin-polyethyleneimine nanogels	—	Xenograft, 151
Diphtheria toxin	Plasmid vector (ovarian specific HE4 and MSLN promoters)	Poly(β-amino ester) polymer-DNA complex	—	Xenograft, 209
Oncogenes HIF1α	siRNA	Liposome	—	Xenograft, 210
PARP1	siRNA	Liposome	—	Xenograft, 157
Src	siRNA	Chitosan	—	Xenograft, 154
Claudin-3	Codelivery of both shRNA plasmid vectors	PLGA nanoparticles	—	Xenograft, 155
CD44 and FAK	Codelivery of both shRNA plasmid vectors	PLGA nanoparticles	—	Xenograft, 156
EphA2 Trial Drug: “siRNA-EphA2-DOPC”	siRNA	Mesoporous silicon loaded with DOPC liposomes	—	Xenograft, 159, 164 Phase I: NCT01591356
EphA2 miR-520d-3p (targets EphB2)	siRNA with codelivery of miRNA	mesoporous silicon loaded with DOPC liposomes	—	Xenograft, 158
Jagged1	siRNA		—	Xenograft, 169
EGFR	siRNA		EphA2	Cell lines, 165
STAT3 and FAK	siRNA	HDL nanoparticles	SR-B1	Xenograft, 166
ID4	siRNA	Peptide nanocomplex	Neuropilin-1	Xenograft, 150
PLXDC1	siRNA	Chitosan	Integrin	Xenograft, 168
—	Non-targeting siRNA	Polyethylenimine nanoparticles	TLR5	Xenograft, 170, 171